Exodus Point Capital Management, LP Cerevel Therapeutics Holdings, Inc. Transaction History

Exodus Point Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$20.26 - $31.91 $546,797 - $861,218	26,989 Added 177.04%	42,234 $922,000
Q2 2023 Aug 10, 2023	BUY	$23.9 - $35.38 $364,355 - $539,368	15,245 New	15,245 $485,000
Q2 2021 Aug 16, 2021	SELL	$12.56 - $29.69 $1.11 Million - $2.62 Million	-88,092 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$12.37 - $17.74 $471,296 - $675,893	38,100 Added 76.21%	88,092 $1.21 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $490,921 - $913,353	49,992 New	49,992 $829,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.